Chronic Inflammatory Demyelinating Polyneuropathy

Neurology
9
Pipeline Programs
6
Companies
14
Clinical Trials
5 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
5
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 13 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

argenx
argenxBelgium - Zwijnaarde
3 programs
2
1
Efgartigimod PH20 SCPhase 41 trial
Empasiprubart IVPhase 31 trial
empasiprubartPhase 31 trial
Active Trials
NCT07091630Recruiting160Est. Jan 2031
NCT06920004Recruiting218Est. Sep 2030
NCT06637072Active Not Recruiting23Est. Feb 2026
CSL Behring
CSL BehringIL - Bradley
6 programs
2
10% liquid formulation of human immunoglobulinPhase 31 trial
IgPro20Phase 31 trial
HOME LINKN/A1 trial
HizentraN/A1 trial
Immune Globulin SubcutaneousN/A1 trial
+1 more programs
Active Trials
NCT03779828Terminated11Est. Jun 2019
NCT04672733Recruiting100Est. Dec 2027
NCT02465359Completed15Est. May 2021
+3 more trials
DT
1 program
1
DNTH103Phase 31 trial
Active Trials
NCT06858579RecruitingEst. Dec 2030
Immunovant
ImmunovantDURHAM, NC
3 programs
3
BatoclimabPhase 2Monoclonal Antibody1 trial
Batoclimab 680 milligramsPhase 21 trial
IMVT-1402Phase 21 trial
Active Trials
NCT07188844Enrolling By InvitationEst. Nov 2028
NCT05581199Active Not RecruitingEst. Jan 2027
NCT07032662RecruitingEst. May 2030
Octapharma
OctapharmaAustria - Vienna
1 program
ImmunoglobulinsN/A1 trial
Active Trials
NCT02111590Completed36Est. Jul 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
argenxEfgartigimod PH20 SC
argenxEmpasiprubart IV
argenxempasiprubart
Dianthus TherapeuticsDNTH103
CSL BehringIgPro20
CSL Behring10% liquid formulation of human immunoglobulin
ImmunovantBatoclimab
ImmunovantIMVT-1402
ImmunovantBatoclimab 680 milligrams
CSL BehringHizentra
CSL BehringHOME LINK
CSL BehringIntravenous Immunoglobulin
CSL BehringImmune Globulin Subcutaneous
OctapharmaImmunoglobulins

Clinical Trials (14)

Total enrollment: 832 patients across 14 trials

NCT06637072argenxEfgartigimod PH20 SC

A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC

Start: Dec 2024Est. completion: Feb 202623 patients
Phase 4Active Not Recruiting
NCT07091630argenxEmpasiprubart IV

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Start: Sep 2025Est. completion: Jan 2031160 patients
Phase 3Recruiting
NCT06920004argenxempasiprubart

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

Start: Aug 2025Est. completion: Sep 2030218 patients
Phase 3Recruiting
NCT06858579Dianthus TherapeuticsDNTH103

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Start: Feb 2025Est. completion: Dec 2030
Phase 3Recruiting
NCT01545076CSL BehringIgPro20

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Start: Mar 2012Est. completion: Sep 2016208 patients
Phase 3Completed
NCT01184846CSL Behring10% liquid formulation of human immunoglobulin

Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy

Start: Nov 2010Est. completion: Nov 201131 patients
Phase 3Completed
NCT07188844ImmunovantBatoclimab

An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Start: Aug 2025Est. completion: Nov 2028
Phase 2Enrolling By Invitation
NCT07032662ImmunovantIMVT-1402

IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Start: Mar 2025Est. completion: May 2030
Phase 2Recruiting
NCT05581199ImmunovantBatoclimab 680 milligrams

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Start: Dec 2022Est. completion: Jan 2027
Phase 2Active Not Recruiting
NCT04672733CSL BehringHizentra

Hizentra® in Inflammatory Neuropathies - pHeNIx Study

Start: Jun 2022Est. completion: Dec 2027100 patients
N/ARecruiting
NCT03779828CSL BehringHOME LINK

Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP

Start: Nov 2017Est. completion: Jun 201911 patients
N/ATerminated
NCT02414490CSL BehringIntravenous Immunoglobulin

IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements

Start: Mar 2015Est. completion: May 202030 patients
N/ACompleted
NCT02465359CSL BehringImmune Globulin Subcutaneous

Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Start: Sep 2014Est. completion: May 202115 patients
N/ACompleted
NCT02111590OctapharmaImmunoglobulins

Immunoglobulin Dosage and Administration Form in CIDP and MMN

Start: Jan 2014Est. completion: Jul 201536 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
10h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
10h ago

Director of Finance

CoMind
London, UK
10h ago

Electronics Engineering Manager

CoMind
London, UK
10h ago

Director of Information Technology

Zavation Medical Products
10h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
5 actively recruiting trials targeting 832 patients
6 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)